A practical reference on AOD-9604: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-11-08 and is reviewed periodically as new material appears.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
dopaquinone + cysteine → 5-S-cysteinyldopa → benzothiazine intermediate → pheomelanin dopaquinone + cysteine → 2-S-cysteinyldopa → benzothiazine intermediate → pheomelanin Also, dopaquinone can be converted to leucodopachrome and follow two more pathways to the eumelanins
Italian merchants, particularly the Venetians, Genoese, and Pisans, took control of international trade, thus reducing the influence of native merchants. The political system grew increasingly extractive and authoritarian, contributing to the empire's collapse in 1204. The fall of Constantinople during the Fourth Crusade in 1204 destroyed centuries of its wealth. Large landholdings were confiscated, and the empire fragmented into smaller rump states ruled by competing factions, making governance inefficient and increasing the costs of doing business. The state gradually lost control over trade practices, price regulations, the outflow of precious metals, and possibly even the minting of coins. Italian merchants further dominated trade as the events of 1204 opened the Black Sea to Western merchants, permanently altering the empire's fortunes. Farmers and manufacturers increasingly produced goods for local use and were affected by the insecurity of constant warfare. Despite these challenges, the empire's mixed economy (characterised by state interventions, public works, and market liberalisation) remained a model of medieval economic adaptability, even as it deteriorated under external pressures.
Large deposits of iron are banded iron formations, a type of rock consisting of repeated thin layers of iron oxides alternating with bands of iron-poor shale and chert. The banded iron formations were laid down in the time between 3,700 million years ago and 1,800 million years ago. Materials containing finely ground iron(III) oxides or oxide-hydroxides, such as ochre, have been used as yellow, red, and brown pigments since pre-historical times. They contribute as well to the color of various rocks and clays, including entire geological formations like the Painted Hills in Oregon and the Buntsandstein ("colored sandstone", British Bunter). Through Eisensandstein (a jurassic 'iron sandstone', e.g. from Donzdorf in Germany) and Bath stone in the UK, iron compounds are responsible for the yellowish color of many historical buildings and sculptures. The proverbial red color of the surface of Mars is derived from an iron oxide-rich regolith. Significant amounts of iron occur in the iron sulfide mineral pyrite (FeS2), but it is difficult to extract iron from it and it is therefore not exploited. In fact, iron is so common that production generally focuses only on ores with very high quantities of it. According to the International Resource Panel's Metal Stocks in Society report, the global stock of iron in use in society is 2,200 kg per capita. More-developed countries differ in this respect from less-developed countries (7,000–14,000 vs 2,000 kg per capita).
Sources: en.wikipedia.org
== Contraindications == Oral ketoconazole has various contraindications, such as concomitant use with certain other drugs due to known drug interactions. Other contraindications of oral ketoconazole include liver disease, adrenal insufficiency, and known hypersensitivity to oral ketoconazole.
Cold Cave would be featured on the soundtrack for Tony Hawk's Pro Skater 5 later that year, and two of their songs were selected by Hawk for inclusion on 2018's Tony Hawk's Skate Jam. In mid-February 2016, a single called "Nothing Is True But You" was released. In Spring, Max G. Morton, who played keyboards for a short portion of the band's early days and also collaborated with Eisold on prose and publishing via the singer's own Heartworm Press, rejoined the band. At end of August 2016, the band shared another single, an almost cacophonic track called "The Idea of Love". In September, they embarked on a domestic mini-tour together with dark electropop act TR/ST. In late September 2017, Cold Cave released a single called "Glory", a track reminiscent of early New Order. The video accompanying the track revealed a full live band featuring, besides the ever-present Eisold and Amy Lee, steady touring member Max G. Morton, Nils Bue (bass/guitar) and Ryan McMahon (drums). The band kicked off a small US tour before heading to Europe to support The Jesus and Mary Chain until mid-October. In early April 2018, the band premiered another song, "You & Me & Infinity", and announced a 26-date North American Spring tour with Choir Boy and Black Marble. At the end of the month, a new EP bearing the title of their latest single was made available digitally. In November of the same year the band headed overseas for a string of selected European dates, again with support from Choir Boy.
== Documentaries == To Mars by A-Bomb: The Secret History of Project Orion The Oakes Atomic Dream 2001: The Science of Futures Past Cool It Nuclear Dynamite Gaia Symphony III The Starship and the Canoe The Day After Trinity The Untold History of the United States The Uncertainty Has Settled A Glorious Accident Freeman Dyson: Space Dreamer
== References == "Wife Stricken in War-Torn China, Husband Develops Own Insulin Lab". Kentucky New Era. 1951-11-06. p. 14. Mclean, Radha (2002), Eva's Insulin Hirsch, James (2006), Cheating Destiny: Living with Diabetes, America's biggest epidemic, Boston: Houghton Mifflin Co., ISBN 0-618-51461-9
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.